Phesgo or trastuzumab and pertuzumab

Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk trastuzumab

Trastuzumab deruxtecan is an effective new treatment for patients with HER2-positive metastatic breast cancer who have been previously treated

trastuzumab For treating certain types of breast, stomach or esophagus cancers, and othersTrastuzumab is available as a biosimilar medication See our biosimilar pamphlet Trastuzumab belongs to class of monoclonal antibody It binds selectively to a protein called human epidermal growth factor receptor 2  Intravenous trastuzumab is effective as a single-agent, and in combination with chemotherapy it significantly improves the median time to disease

ซัคเซสมอร์ Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 -positive breast cancer and